Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phathom Pharmaceuticals, Inc. filings document financial reporting, governance, capital structure and product-development disclosures for a Nasdaq-listed biopharmaceutical company focused on gastrointestinal diseases. Form 8-K reports include quarterly and annual results, preliminary financial information, material agreements, financing-related updates, and other event disclosures tied to VOQUEZNA® commercialization and clinical development.
Proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. The filing record also describes registered common stock, risk-oriented forward-looking statements, and clinical or publication updates involving VOQUEZNA in GERD, non-erosive reflux disease and eosinophilic esophagitis.
FIELDS HEIDI reported acquisition or exercise transactions in this Form 4 filing.
Phathom Pharmaceuticals director Heidi Fields received a grant of 24,122 Restricted Stock Units (RSUs) on May 19, 2026 under the company’s Non-Employee Director Compensation Program. All RSUs vest in full on the earlier of the first anniversary of grant or the next annual stockholder meeting, contingent on continued board service. Following this award, Fields holds 54,122 shares of common stock, reflecting routine equity compensation with no cash purchase involved.
Phathom Pharmaceuticals director Michael F. Cola received 24,122 Restricted Stock Units (RSUs) as an equity award. The grant was made under the company’s Non-Employee Director Compensation Program and is a compensation-related acquisition, not an open-market stock purchase.
The RSUs will vest 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, as long as Cola continues serving on the board through that date. Each RSU converts into one share of common stock, bringing his reported direct holdings to 63,920 shares after the grant.
Phathom Pharmaceuticals director Frank Karbe received an equity grant. On May 19, 2026, he was awarded 24,122 Restricted Stock Units under the company’s Non-Employee Director Compensation Program at no cash cost. Following this grant, he holds 91,622 shares of common stock directly. The RSUs vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, conditioned on his continued Board service. Each RSU converts into one share of common stock when it vests.
Phathom Pharmaceuticals director Theodore R. Schroeder received an equity award of 24,122 shares in the form of Restricted Stock Units (RSUs). These RSUs were granted under the company’s Non-Employee Director Compensation Program at no cash cost to him, increasing his direct holdings to 45,122 shares.
The award vests 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, as long as he continues serving on the board. Each RSU will convert into one share of common stock upon vesting, aligning his compensation with shareholder outcomes rather than representing an open-market purchase.
Phathom Pharmaceuticals, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected Class I directors Steven Basta, Theodore R. Schroeder, and Mark Stenhouse to three-year terms expiring at the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, with 64,482,757 votes for and limited opposition. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 44,449,761 votes for and 2,532,145 against. No other matters were brought to a vote.
Phathom Pharmaceuticals reported strong first-quarter 2026 growth driven by its VOQUEZNA franchise but remained unprofitable. Product revenue reached $58.3 million, up from $28.5 million a year earlier, as prescription volume and prescriber adoption increased, mainly for GERD indications.
Net loss narrowed to $30.4 million from $94.3 million, helped by higher gross profit and significantly lower selling, general and administrative expenses. Phathom ended March 31, 2026 with $180.9 million in cash and cash equivalents, while carrying $175.0 million of term debt and a $380.9 million revenue interest financing liability tied to vonoprazan sales.
Phathom Pharmaceuticals reported strong first quarter 2026 momentum as it continues its shift to gastrointestinal (GI) markets. Net product revenue reached $58.3 million, more than double the prior year’s first quarter, driven by growing VOQUEZNA prescriptions among GI specialists.
Gross profit was $46.3 million, and operating loss narrowed sharply to $15.5 million from $78.9 million a year earlier as total operating expenses fell to $61.8 million, with selling, general and administrative costs dropping to $54.0 million. On a non-GAAP basis, adjusted net loss improved to $14.7 million, or $0.18 per share.
Phathom ended March 31, 2026 with $180.9 million in cash and cash equivalents and continues to carry a stockholders’ deficit. Management reiterated full-year 2026 guidance and expects to achieve operating profitability beginning in the third quarter and for the full year 2026, and to reach cash flow positivity in 2027.
Phathom Pharmaceuticals, Inc. is soliciting proxies for its 2026 annual stockholder meeting, to be held virtually on May 19, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on March 23, 2026, when 79,430,117 common shares were outstanding, may vote.
Stockholders will vote on electing three Class I directors to terms ending at the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for 2026, and approving named executive officer compensation on a non-binding advisory “say‑on‑pay” basis. The proxy describes board composition, committee structures, director independence, director and committee retainers, equity grants, and significant stockholders’ ownership, as well as detailed voting procedures and the treatment of abstentions and broker non‑votes.
Phathom Pharmaceuticals, Inc. Schedule 13G filing reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander together beneficially hold 4,178,411 shares of common stock, representing 5.3% of the class as of 03/06/2026. The filing discloses shared voting and shared dispositive power over those 4,178,411 shares.